Biocon Q1 results

Biocon's consolidated revenue for Q1 FY25 reached INR 4,567 crore, marking a 30% year-on-year increase, with a net profit surging six-fold to INR 660 crore, largely due to a one-time gain from its collaboration with Eris Lifesciences. The company's EBITDA soared to INR 1,755 crore, reflecting a significant improvement in margins. However, revenue from operations saw only a slight increase, rising marginally to INR 3,433 crore, which fell short of analysts' expectations. Biocon's outlook remains optimistic for H2 FY25, with anticipated growth from new product launches in the biosimilars and generics sectors, including Liraglutide. Despite challenges in the generics segment, the company expects improved prospects for Syngene amid a revitalized biotech funding environment in the U.S.